Clinical Pearls

Dr Rubin reviews the results of phase 3 trials of guselkumab for treatment of Crohn's disease among patients who are bionaive, bioexposed, and biointolerant or who failed to respond to biologics. 

Dr James D. Lewis recaps his presentation on using diet —including the Crohn's Disease Exclusion Diet, the Low FODmap Diet, and the Mediterranean diet—as an adjunct to medical therapy for Crohn's disease, and the potential for diet to perhaps...

Dr Dubinsky stresses that virtually all patients with Crohn's disease should be treated quickly after diagnosis with approved and effective therapies—which do not include 5-ASAs— to help prevent complications and change the natural history of...

Dr David Rubin provides a guideline for optimizing adalimumab and infliximab in treating patients with inflammatory bowel disease.

Dr Laura Raffals from Mayo Clinic discusses her top clinical tips for ensuring proper diagnosis, treatment, monitoring, and management of patients with ulcerative colitis.